Back to search

Article

Lysergic acid diethylamine for generalized anxiety disorder

2026-03-11

Abstract excerpt

<p>Letter in reply to Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;doi:10.1001/jama.2025.13481 (unpublished, rejected by the journal)</p>

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f3096586-794d-5373-8809-83e8f3d42a7f
DOI
10.31234/osf.io/6shqy_v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 11 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Lysergic acid diethylamine for generalized anxiety disorderDOI 10.31234/osf.io/6shqy_v1
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Semantic proximity
Psychedelic Therapy: A Primer for Primary Care Clinicians—MescalineSemantic proximity
Genetic deletion of β-arrestin 2 modulates LSD-stimulated behaviors in miceSemantic proximity
Evaluation of comparative efficacy of Celastrus paniculatus (Jyotishmati) capsule versus sertraline capsule in the management of Chittodvega (generalized anxiety disorder): protocol for a randomized controlled trialSemantic proximity
Safety and Efficacy of Two Doses of Tandospirone Citrate for Generalized Anxiety Disorder: A Multicenter Randomized Controlled TrialSemantic proximity
ED95 of esketamine for reducing preoperative anxiety in children of different agesSemantic proximity
Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity
Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity
Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity
Emetophobia appears to be the most common specific phobia that requires treatmentSemantic proximity
Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study.Semantic proximity
Select a neighboring publication to make it the new centre.